ATE413399T1 - Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen - Google Patents

Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen

Info

Publication number
ATE413399T1
ATE413399T1 AT03745294T AT03745294T ATE413399T1 AT E413399 T1 ATE413399 T1 AT E413399T1 AT 03745294 T AT03745294 T AT 03745294T AT 03745294 T AT03745294 T AT 03745294T AT E413399 T1 ATE413399 T1 AT E413399T1
Authority
AT
Austria
Prior art keywords
morpholinyl
treatment
diseases associated
urea derivatives
inflammatory processes
Prior art date
Application number
AT03745294T
Other languages
English (en)
Inventor
Rachael Ann Ancliff
Caroline Mary Cook
Colin David Eldred
Paul Martin Gore
Lee Andrew Harrison
Martin Alistair Hayes
Simon Teanby Hodgson
Duncan Bruce Judd
Suzanne Elaine Keeling
Xiao Qing Lewell
Gail Mills
Graeme Michael Robertson
Stephen Swanson
Andrew John Walker
Mark Wilkinson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0207434A external-priority patent/GB0207434D0/en
Priority claimed from GB0301608A external-priority patent/GB0301608D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE413399T1 publication Critical patent/ATE413399T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT03745294T 2002-03-28 2003-03-27 Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen ATE413399T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0207434A GB0207434D0 (en) 2002-03-28 2002-03-28 Novel compounds
GB0301608A GB0301608D0 (en) 2003-01-24 2003-01-24 Novel compounds

Publications (1)

Publication Number Publication Date
ATE413399T1 true ATE413399T1 (de) 2008-11-15

Family

ID=28676494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03745294T ATE413399T1 (de) 2002-03-28 2003-03-27 Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen

Country Status (23)

Country Link
US (1) US7622464B2 (de)
EP (1) EP1487828B1 (de)
JP (1) JP4465195B2 (de)
KR (1) KR20040093488A (de)
CN (1) CN1656092A (de)
AR (1) AR040403A1 (de)
AT (1) ATE413399T1 (de)
AU (1) AU2003226757A1 (de)
BR (1) BR0308780A (de)
CA (1) CA2480106A1 (de)
CY (1) CY1108652T1 (de)
DE (1) DE60324535D1 (de)
DK (1) DK1487828T3 (de)
ES (1) ES2315519T3 (de)
IL (1) IL164047A0 (de)
IS (1) IS7444A (de)
MX (1) MXPA04009459A (de)
NO (1) NO20044448L (de)
PT (1) PT1487828E (de)
RU (1) RU2004127928A (de)
SI (1) SI1487828T1 (de)
TW (1) TW200400035A (de)
WO (1) WO2003082861A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004089296A2 (en) 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1765311A4 (de) 2004-03-16 2009-04-29 Univ California Verringerung von nephropathie mit hemmern der löslichen epoxid-hydrolase und von epoxyeicosanoiden
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
ES2542228T3 (es) 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
CA2579207C (en) 2004-09-08 2011-10-18 Mitsubishi Pharma Corporation Morpholine compound
WO2006045119A2 (en) 2004-10-20 2006-04-27 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
TW200808321A (en) 2005-12-15 2008-02-16 Cytokinetics Inc Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
AR059826A1 (es) 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
US8222243B2 (en) * 2007-08-27 2012-07-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
EP2528604B1 (de) 2010-01-29 2017-11-22 The Regents of the University of California Acylpiperidinhemmer aus löslicher epoxidhydrolase
RU2512293C1 (ru) * 2012-12-13 2014-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет" Способ получения этил 1,2,4-оксадиазол-5-карбоксилатов
CN107362362B (zh) * 2017-07-20 2019-01-01 复旦大学 Sirt1抑制剂在预防和治疗放射引起的肠道疾病中的应用
EP4178948A2 (de) * 2020-07-29 2023-05-17 Universidade de Santiago de Compostela Funktionalisierte isonitrile und produkte, herstellung und verwendungen davon
JP2023538255A (ja) * 2020-08-03 2023-09-07 グローバル ブラッド セラピューティクス インコーポレイテッド ピルビン酸キナーゼ活性化化合物としての尿素誘導体
CN119330881A (zh) * 2024-09-06 2025-01-21 苏州汉德创宏生化科技有限公司 一种3-氨甲基-1-h吡唑的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851526A (en) 1987-09-04 1989-07-25 Schering A.G. 1-(4-Substituted phenyl)-1H-imidazoles compounds
JP3087763B2 (ja) * 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5219856A (en) 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
EP0759918A1 (de) 1994-05-19 1997-03-05 MERCK SHARP & DOHME LTD. Indol-3-ylalkyl-piperidin-piperazin, -piperidin und tetrahydropyridin-derivate als 5-ht1 d-alpha agonisten
EP0772611A1 (de) 1994-07-20 1997-05-14 Byk Gulden Lomberg Chemische Fabrik GmbH Piperazinothiopyridine zur bekämpfung von helicobacter-bakterien
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
WO1997047601A1 (en) 1996-06-11 1997-12-18 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
US5919776A (en) 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
IT1293807B1 (it) 1997-08-01 1999-03-10 Recordati Chem Pharm Derivati 1- (n-fenilaminoalchil) piperazinici sostituiti alla posizione 2 dell'anello fenilico
WO1999021848A2 (en) 1997-10-27 1999-05-06 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US6031097A (en) 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2-哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
AR035205A1 (es) 2000-09-29 2004-05-05 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
IL155092A0 (en) * 2000-09-29 2003-10-31 Glaxo Group Ltd Compounds useful in the treatment of inflammatory diseases

Also Published As

Publication number Publication date
CA2480106A1 (en) 2003-10-09
EP1487828B1 (de) 2008-11-05
DK1487828T3 (da) 2009-02-02
TW200400035A (en) 2004-01-01
EP1487828A2 (de) 2004-12-22
SI1487828T1 (sl) 2009-04-30
NO20044448L (no) 2004-10-26
CY1108652T1 (el) 2014-08-13
PT1487828E (pt) 2009-01-06
BR0308780A (pt) 2004-12-28
US7622464B2 (en) 2009-11-24
DE60324535D1 (de) 2008-12-18
IL164047A0 (en) 2005-12-18
KR20040093488A (ko) 2004-11-05
CN1656092A (zh) 2005-08-17
IS7444A (is) 2004-09-13
WO2003082861A3 (en) 2004-03-11
JP2005526815A (ja) 2005-09-08
MXPA04009459A (es) 2005-01-25
US20060063765A1 (en) 2006-03-23
AU2003226757A1 (en) 2003-10-13
RU2004127928A (ru) 2005-06-27
JP4465195B2 (ja) 2010-05-19
AR040403A1 (es) 2005-04-06
ES2315519T3 (es) 2009-04-01
WO2003082861A2 (en) 2003-10-09

Similar Documents

Publication Publication Date Title
DE60324535D1 (de) Morpholinyl-harnstoff-derivative fuer die behandlung von krankheiten verbunden mit entzuendlichen prozessen
ATE374196T1 (de) Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE418554T1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
ATE417037T1 (de) Diarylharnstoffderivate, die sich zur behandlung von proteinkinaseabhängigen krankheiten eignen
NL1026329A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
NL1025071A1 (nl) Verbindingen voor de behandeling van abnormale celgroei.
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
ATE345331T1 (de) Verbindungen verwendbar für die behandlung von entzündungskrankheiten
DE60233414D1 (de) Kombinationen für die behandlung entzündlicher erkrankungen
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
NL1026327A1 (nl) 2-Amino-pyridinederivaten toepasbaar voor de behandeling van ziekten.
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DE60239558D1 (de) Kombinationen für die behandlung von immun-entzündlichen erkrankungen
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
NL1026203A1 (nl) Verbindingen toepasbaar voor de behandeling van ziekten.
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487828

Country of ref document: EP